GE Healthcare acquires rights to sell cardiovascular stress agent outside North America
GE Healthcare’s life sciences business acquired the rights to produce and sell regadenoson (Rapiscan) in territories outside the U.S., Canada and Mexico.
The company purchased the rights from Rapidscan Pharma Solutions. Brent K. Blackburn, PhD, Daniel K. Spiegelman and Louis G. Lange, MD, PhD, founded Rapidscan in 2010 to commercialize regadenoson, a pharmacological stress agent used to diagnose cardiovascular disease.
The FDA and European Medicines Agency have approved regadenoson, a selective coronary vasodilator used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients.
GE Healthcare said in a news release that regadenoson reduces the risks of MPI tests in patients who cannot exercise due to asthma, chronic obstructive pulmonary disease or other conditions.
GE Healthcare distributes regadenoson in the United Kingdom and Germany, while Astellas distributes the agent in the U.S., Canada and Mexico.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.